ClinicalTrials.gg
RecruitingNCT06120270Updated Jun 10, 2026

CeraFlex PFO Closure System PMCF Study

An observational study in Patent Foramen Ovale, sponsored by Lifetech Scientific (Shenzhen) Co., Ltd.. Recruiting at 15 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Lifetech Scientific (Shenzhen) Co., Ltd. (part of LifeTech Scientific Corporation) · Observational

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
180
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to compile real-world data on patient outcomes and evaluate the procedural success and performance of the CeraFlex™ PFO Closure System.

Read the detailed description

This is a multicenter, prospective, observational, single-arm, open-label, post-market Study. The study device is the Lifetech CeraFlex PFO closure system, which is composed of a) CeraFlex PFO Occluder, and b) SteerEase Introducer. The PFO Closure System is indicated for the non-surgical closure of Patent Foramen Ovale (PFO), and the study objective is to collect real-world data on patient outcomes and evaluate the procedural success and performance of the CeraFlex PFO Closure System.

The estimated enrollment period is approximately 18 months, and each subject will followed 24 months post-procedure. The assessment schedule at discharge, 1-3 months follow-up, 6 months follow-up, 12 months follow-up, and 24 months follow-up.

Electronic Date Capture (EDC) System will be used for this Study.

02

Conditions studied

  • Patent Foramen Ovale

Browse trials for

Keywords

  • Lifetech
  • Patent Foramen Ovale
  • PFO
  • CeraFlex
  • CeraFlex PFO
  • CeraFlex PFO Closure System
03

In context

Foramen Ovale, Patent

136 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.

This study's planned enrollment of 180 is below the median of 254 across 59 observational studies indexed under Foramen Ovale, Patent.

Browse Foramen Ovale, Patent studies →

Lead sponsor

Lifetech Scientific (Shenzhen) Co., Ltd. is the lead sponsor of 44 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with PFO and need non-surgical closure of PFO.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with indication(s) for PFO Occluder Closure in the Instruction For Use (IFU):

    1. Confirmed PFO by medical examinations;
    2. Associated with recurrent migraine/headache or or cryptogenic stroke.
  2. Patient characteristics consistent with the corresponding IFU \& Device Size Selection:

    1. Measure the distance from the defect to the aorta root;
    2. Measure the distance from the defect to the superior vena cava (SVC) rim; select a device with the radius of the right disc that will not exceed the lesser of these two distances.
  3. Patients who are willing to comply with all study procedures and be available for the duration of the study.
  4. Patients or legally authorized representative(s) who are willing and capable of providing .

Exclusion criteria

Exclusion Criteria:

  1. Age \<18 years or Age >85 years.
  2. Patient with a history of ongoing Atrial Fibrillation (AF).
  3. Patient with or other illness where is less than 1 year.
  4. Patient not covered by a social security scheme.
  5. Patients who are participating in an drug or device study currently.
  6. Women of who are, or plan to become pregnant during the time of the study (method of assessment upon physician's discretion).
  7. Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
  8. Any mentioned in the corresponding IFU:

    1. Patients known to have intracardiac thrombi, especially left atrial or left atrial appendage thrombi, demonstrated by echocardiography. Patients known to have a bleeding disorder, untreated ulcer, or any other contraindications to aspirin therapy unless another anti- agent can be administered for 6 months.
    2. Anatomy in which the CeraFlexTM PFO device of the required size would interfere with intra-cardiac structure or intra-vascular structure, such as a pulmonary vein, or aorta root.
    3. Patients whose heart or vein size is too small to allow TEE probing or catheterization.
    4. Patients who are in the condition, e.g. active infection, which would cause them to be poor candidates for cardiac catheterization.
    5. Patients known to have sepsis within one month prior to implantation, or any systemic infection that cannot be successfully treated prior to device placement.
    6. Patients whose heart does not have enough tissue to secure the device.
    7. Patients with hypercoagulation disease.
    8. Any patient for whom the radius of the device is greater than the distance from the patent foramen ovale to the aortic root or superior vena cava.

      • No contraindications specified in the SteerEase introducer IFU.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No

Interventions

  • DeviceCeraFlex PFO Closure System

    The Lifetech CeraFlex™ PFO occluder device is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).

06

What researchers measure

Primary outcomes

  1. Procedural success rate

    Procedure success is defined as a composite of : 1. absence of peri-procedural stroke-related events (ischemic stroke, cryptogenic stroke, or TIA), device embolization, cardiac or vascular perforation, or death, at discharge or 7 days post-procedure, whichever comes first; 2. successful implantation of the device at the procedure.

    Time frame: Procedure/at discharge or 7 days post-procedure, whichever comes first

Secondary outcomes

  1. Residual shunt

    Residual shunt was classified on the basis of the estimated number of microbubbles detected in the left atrium within three cardiac cycles after appearance in the right atrium, as observed on cTTE/cTEE while the patient was at rest or during Valsalva procedure. The presence of 0 microbubbles was classified as no shunt, 1 to 5 microbubbles as small, 6 to 25 microbubbles as moderate, and more than 25 microbubbles as large.

    Time frame: At procedure, 6 months and 12 months post-implantation

  2. Rate of stroke related events

    Ischemic stroke, cryptogenic stroke, or TIA

    Time frame: From attempted procedure up to 24 months post-implantation

  3. Rate of Device Deficiencies

    Including device malfunctions, failures, and non-conformances

    Time frame: From attempted procedure up to 24 months post-implantation

  4. Incidence of Serious Adverse Event

    SAE

    Time frame: From attempted procedure up to 24 months post-implantation

  5. Incidence of death

    Death

    Time frame: From attempted procedure up to 24 months post-implantation

07

Study locations

13 of 15 sites recruiting
  • Kardiologisch-Angiologische Praxis - Herzzentrum Bremen
    Bremen, Germany
    Recruiting
    • Martin Gödde, Dr · Contact
  • Heart Center Dresden
    Dresden, Germany
    Not yet recruiting
    • Felix Woitek, Dr · Contact
  • Hospital Fürth
    Fürth, Germany
    Recruiting
    • Rittger, Prof · Contact
  • Kath. Marienkrankenhaus gGmbH
    Hamburg, Germany
    Recruiting
    • Dimitry Schewel, Dr · Contact
  • Universitätsklinikum Hamburg-Eppendorf (UKE)
    Hamburg, Germany
    Recruiting
    • Daniel Kalbacher, Dr. · Contact
  • German Heart Center Leipzig
    Leipzig, Germany
    Recruiting
    • Marcus Sandri, Dr · Contact
  • Klinikum St. Georg gGmbH Leipzig
    Leipzig, Germany
    Not yet recruiting
    • Norbert Klein, Dr · Contact
  • German Heart Center Munich
    Munich, Germany
    Recruiting
    • Stanimir Georgiev, Dr · Contact
  • Herzzentrum Trier
    Trier, Germany
    Recruiting
    • Nikos Werner, Prof. · Contact
  • University clinic Tübingen
    Tübingen, Germany
    Recruiting
    • Michal Droppa, Dr · Contact
  • Chonnam National University Hospital
    Gwangju, Gwangju 57393, South Korea
    Recruiting
  • Yeungnam University Medical Center
    Daegu, South Korea
    Recruiting
  • ASAN Medical Center
    Seoul, South Korea
    Recruiting
  • Samsung Medical Center
    Seoul, South Korea
    Recruiting
  • Catholic University of Korea St. Vincent's Hospital
    Suwon, South Korea
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2023
First posted
Nov 7, 2023
StartActual
Nov 3, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2028
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06120270
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
Nov 3, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jun 10, 2026

Study contacts

Kadir Shemsi, CTM
Contact
Kadirr@lifetechmed.com
+86-176-2130-9203
Marcus Sandri, Dr
principal investigator · German Heart Center Leipzig

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion